Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. LCC Ltd.
WARNING LETTER
•LCC Ltd.•March 22, 2024

LCC Ltd. – FDA Warning Letter, Mar 22, 2024

Record Details

The FDA issued a Warning Letter to LCC Ltd. following a March 18-22, 2024 inspection, citing significant Current Good Manufacturing Practice (CGMP) violations and the marketing of unapproved and misbranded drug products. The firm's drug products are considered adulterated. CGMP deficiencies include failure to adequately test components for identity, purity, strength, and quality, and to validate supplier test analyses, especially for high-risk components like glycerin, propylene glycol, and (b)(4) for DEG/EG contamination (21 CFR 211.84(d)(1), 211.84(d)(2)). The Quality Control Unit failed to ensure CGMP compliance and product specifications (21 CFR 211.22), and laboratory records lacked complete, trustworthy data, indicating severe data integrity issues (21 CFR 211.194(a)). Additionally, "SOL, Mouthwash, zero alcohol, frosty mint" and "Oriox, Cool Breath, ORAL RINSE, Mild mint" are deemed unapproved new drugs (21 U.S.C. 355(a), 331(d)) as they do not conform to applicable OTC monographs or ANPR conditions. These products are also misbranded (21 U.S.C. 352(ee)) for non-compliance with Section 505G requirements. The FDA noted repeat violations, indicating inadequate executive management oversight. The firm remains on Import Alert 66-40. LCC Ltd. must conduct a full risk assessment for products with high-risk components, implement CAPAs for supply chain security, and undertake comprehensive data integrity remediation, including a third-party audit. If drug manufacturing resumes, a qualified consultant must perform a six-system audit. A response detailing corrective actions is required within 15 working days, with potential consequences including continued import refusal and withheld application approvals.

Company
LCC Ltd.
Inspection date
March 22, 2024
Product type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Francis Godwin (Director)
  • Tina Smith (Director)
View Company Profile

ID · 5858f6f9-63bf-4e2c-a2ac-4d9f87e9b032

Violation Codes10
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 21121 CFR 211.84(d)(1)21 CFR 211.84(d)(2)21 CFR 211.2221 CFR 211.194(a)21.U.S.C. 355(a)21 U.S.C. 331(d)21 U.S.C. 352(ee)

Full citation text and observation details available on the Dashboard.

Other documents for LCC Ltd.
  • 483 - 2024-03-22March 22, 2024
  • WARNING_LETTER - 2023-08-03August 3, 2023

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore LCC Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.